{"id":"W2944165579","doi":"10.1158/1538-7445.sabcs18-p1-13-05","title":"Abstract P1-13-05: Efficacy and safety of eflapegrastim confirmed in reducing severe neutropenia in breast cancer patients treated with myelosuppressive chemotherapy in the second Phase 3 randomized controlled multinational trial compared to pegfilgrastim (RECOVER trial)","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Pegfilgrastim; Medicine; Neutropenia; Docetaxel; Breast cancer; Internal medicine; Febrile neutropenia; Clinical endpoint; Cyclophosphamide; Oncology; Phases of clinical research; Chemotherapy; Cancer; Surgery; Clinical trial","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002421788,0.001669356,0.001933239,0.0003264019,0.0003497241,0.001078794,0.0009257253,0.001529445,0.007341127],"category_scores_gemma":[0.001368822,0.000524158,0.001820269,0.0002863912,0.0008899617,0.00100973,0.00040783,0.003793713,0.0009054133],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008360075,"about_ca_system_score_gemma":0.001484542,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005818953,"about_ca_topic_score_gemma":0.00150917,"domain_scores_codex":[0.9994513,0.0003128829,0.00003429367,0.00008234364,0.00003943205,0.00007972773],"domain_scores_gemma":[0.9990779,0.0002086738,0.0002589649,0.00008366511,0.00006423722,0.0003065902],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.96901,0.009484496,0.0008383978,0.0003941612,0.0006526028,0.00004161241,0.00004549357,0.0003491882,0.003158221,0.00009527901,0.001365434,0.01456508],"study_design_scores_gemma":[0.8838866,0.1115195,0.002073624,0.00003135573,0.0003073142,0.00005871748,0.00001330222,0.0004079705,0.0008338614,0.0001033831,0.0007528555,0.00001145912],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9870589,0.002394022,0.0004688689,0.001335282,0.0002720425,0.004744936,0.001592652,0.0001304367,0.002002815],"genre_scores_gemma":[0.9808112,0.001556144,0.002171769,0.001779394,0.0005189326,0.006365201,0.002808046,0.00004193043,0.003947434],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007341127,"threshold_uncertainty_score":0.02455848,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02701083480219315,"score_gpt":0.3725926572760232,"score_spread":0.3455818224738301,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}